Mass Torts and Pharmacy Liens: Coordination Challenges and When They Apply

James Wong — Founder & Pharmacist, LienScripts | January 21, 2025 | 8 min read

Mass tort plaintiffs face the same medication access challenges as individual PI plaintiffs — but the coordination of pharmacy liens across large plaintiff populations requires a different approach than case-by-case enrollment.

This post is for informational purposes only and does not constitute legal advice.

Mass Torts Are PI Cases With Scale Complexity

A mass tort plaintiff is, at the individual level, a personal injury plaintiff. They were harmed by a defendant's conduct, they have ongoing medical needs related to that harm, and they may lack insurance coverage for prescriptions attributable to the tortious conduct.

The pharmacy lien mechanism applies the same way it applies in any PI case — the plaintiff accesses medications through the lien, the lien is repaid at settlement or judgment. What changes in a mass tort is the administrative complexity of coordinating that mechanism across dozens, hundreds, or thousands of individual plaintiffs.

[!KEY] A mass tort plaintiff's medication access need is identical to any individual PI plaintiff's — the pharmacy lien operates at the individual level regardless of docket size, and each plaintiff with significant ongoing prescription needs and limited insurance coverage should be evaluated for enrollment.

The Individual Plaintiff's Medication Need

Before addressing coordination, the underlying clinical reality: mass tort plaintiffs often have significant, ongoing prescription medication needs directly attributable to the harm at issue.

Pharmaceutical mass torts (defective drug cases): Plaintiffs who suffered adverse effects from a defective pharmaceutical — organ damage, neurological harm, cardiac complications — often require ongoing prescriptions to manage the conditions the drug caused. These prescriptions are causally connected to the tort and are appropriate for pharmacy lien coverage.

Device mass torts (failed implants, defective medical devices): Plaintiffs with failed devices — particularly orthopedic implants, mesh products, cardiac devices — may require ongoing pain management, anti-inflammatory medications, antibiotics for revision surgeries, and medications for systemic complications. These are injury-related prescriptions.

Toxic tort / environmental mass torts (chemical exposure, contaminated water): Plaintiffs with respiratory, neurological, or oncological conditions from toxic exposure require ongoing prescription management. Cancer treatment, respiratory medications, neurological agents — all potentially lien-coverable if causally connected to the exposure.

Consumer product mass torts: Plaintiffs injured by defective consumer products (similar to individual product liability cases) require injury-related medication management throughout the litigation.

Coordination Challenges in Mass Torts

Individual Enrollment at Scale

Pharmacy lien enrollment is an individual transaction — each plaintiff signs a lien agreement, provides their information, and has medications dispensed to them individually. In a mass tort with hundreds of plaintiffs, this requires a coordination infrastructure that most firms handling mass torts need to build proactively.

[!TIP] If your firm handles a significant number of mass tort plaintiffs with medication access needs, establish a mass enrollment protocol with the pharmacy lien provider before individual needs arise — one-at-a-time enrollment across hundreds of plaintiffs is administratively unsustainable.

Recommendation: If your firm is handling a significant number of mass tort plaintiffs with medication access needs, contact pharmacy lien providers early to establish a mass enrollment protocol — rather than enrolling plaintiffs one at a time as the need arises.

Causal Connection Documentation

In mass torts, causation is often contested at the aggregate level (general causation) and the individual level (specific causation). For pharmacy lien purposes, the relevant question is specific causation for each plaintiff: are this specific plaintiff's prescriptions causally connected to the harm caused by the defendant?

This is more complex in a pharmaceutical mass tort (where the plaintiff may have pre-existing conditions for which the drug was prescribed) than in a toxic tort (where the plaintiff may have no prior history of the conditions the exposure caused). The causal connection question for lien purposes should be addressed the same way it's addressed for damages: with treating physician documentation attributing the medications to the tort-related harm.

MDL Settlement Structures

Mass tort cases that resolve through MDL settlements (Multi-District Litigation) have complex allocation methodologies — matrix-based, points-based, or tiered systems that calculate each plaintiff's settlement share based on injury severity, duration, and other factors.

Pharmacy lien amounts are typically included as economic damages components in MDL settlement allocation calculations. Attorneys handling MDL cases should ensure their plaintiff's pharmacy lien amount is properly documented and submitted in the MDL claims process.

Coordinating With MDL Common Benefit Counsel

In MDLs with a leadership structure, common benefit counsel may have established protocols for economic damages documentation. Pharmacy liens should be documented in the same manner as other medical expenses — with itemized statements available for submission to the claims administrator.

[!KEY] In MDL settlements with matrix-based allocation, the pharmacy lien itemization functions as documented economic damages — submitting it through the claims administrator process ensures it is included in the allocation calculation rather than absorbed as an unreimbursed expense the plaintiff absorbs from their share.

When Pharmacy Liens Are Most and Least Useful in Mass Torts

Most useful: Plaintiffs with significant, ongoing prescription needs for conditions causally attributed to the tort; plaintiffs without insurance coverage for those medications; plaintiffs in cases with extended litigation timelines where medication needs span years.

Least useful: Plaintiffs whose medication needs are modest or short-term; plaintiffs whose health insurance covers the relevant prescriptions without injury-exclusion complications; plaintiffs in mass torts that are expected to resolve quickly through existing settlement programs.

Practical Starting Point for Mass Tort Attorneys

If you're handling mass tort cases and haven't established a pharmacy lien protocol for your plaintiff population, the first step is a conversation with a pharmacy lien provider to assess whether the specific mass tort (the defendant, the injury type, the medication needs) is appropriate for lien-based medication access.

Not every mass tort plaintiff needs a pharmacy lien. But for plaintiffs with significant, ongoing prescription needs and limited insurance coverage, the same logic that applies in individual PI cases applies here.

[!KEY] The causal connection question — are these specific prescriptions attributable to the tort-related harm rather than a pre-existing condition? — must be addressed at enrollment for mass tort pharmacy liens, and the treating physician's documentation attributing the medications to the harm is the most defensible foundation for that attribution.

For more on pharmacy lien coverage for complex civil litigation, visit for attorneys.